SymBio Pharmaceuticals Limited (4582.T)
JPY 154.0
(-1.28%)
JPY 154.0
(-1.28%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -714 Million JPY | -136.6% |
| 2022 | 2.2 Billion JPY | 76.19% |
| 2021 | 1.1 Billion JPY | 122.32% |
| 2020 | -4.44 Billion JPY | -16.42% |
| 2019 | -4.26 Billion JPY | -62.91% |
| 2018 | -2.62 Billion JPY | 33.13% |
| 2017 | -3.91 Billion JPY | -71.1% |
| 2016 | -2.28 Billion JPY | 12.09% |
| 2015 | -2.6 Billion JPY | -137.44% |
| 2014 | -1.09 Billion JPY | 31.11% |
| 2013 | -1.59 Billion JPY | 7.41% |
| 2012 | -1.71 Billion JPY | 17.53% |
| 2011 | -2.09 Billion JPY | -248.79% |
| 2010 | -606.27 Million JPY | -193.69% |
| 2009 | -203.68 Million JPY | -247.54% |
| 2008 | 27.58 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -806.7 Million JPY | -53.86% |
| 2024 Q3 | -1.29 Billion JPY | -46.14% |
| 2024 Q2 | -917.22 Million JPY | -14.47% |
| 2023 Q4 | -504.62 Million JPY | -210.79% |
| 2023 Q1 | 48.75 Million JPY | -86.99% |
| 2023 FY | - JPY | -136.6% |
| 2023 Q2 | -189.45 Million JPY | -488.63% |
| 2023 Q3 | -162.37 Million JPY | 14.3% |
| 2022 Q4 | 374.76 Million JPY | 73.2% |
| 2022 FY | - JPY | 76.19% |
| 2022 Q1 | 509.2 Million JPY | -13.95% |
| 2022 Q2 | 863.27 Million JPY | 69.53% |
| 2022 Q3 | 216.38 Million JPY | -74.93% |
| 2021 Q3 | 619.18 Million JPY | 3874.71% |
| 2021 Q1 | -210.71 Million JPY | 84.55% |
| 2021 FY | - JPY | 122.32% |
| 2021 Q4 | 591.76 Million JPY | -4.43% |
| 2021 Q2 | 15.57 Million JPY | 107.39% |
| 2020 FY | - JPY | -16.42% |
| 2020 Q2 | -878.03 Million JPY | 8.72% |
| 2020 Q1 | -961.91 Million JPY | -25.7% |
| 2020 Q3 | -1.3 Billion JPY | -48.34% |
| 2020 Q4 | -1.36 Billion JPY | -4.71% |
| 2019 Q3 | -1.52 Billion JPY | -7.4% |
| 2019 Q2 | -1.41 Billion JPY | -138.13% |
| 2019 FY | - JPY | -62.91% |
| 2019 Q4 | -765.26 Million JPY | 49.79% |
| 2019 Q1 | -595.94 Million JPY | 20.44% |
| 2018 Q4 | -749.04 Million JPY | -26.67% |
| 2018 FY | - JPY | 33.13% |
| 2018 Q1 | -704.69 Million JPY | -60.91% |
| 2018 Q2 | -610.99 Million JPY | 13.3% |
| 2018 Q3 | -591.33 Million JPY | 3.22% |
| 2017 Q3 | -2.27 Billion JPY | -218.62% |
| 2017 FY | - JPY | -71.1% |
| 2017 Q1 | -526.39 Million JPY | -31.57% |
| 2017 Q2 | -713.15 Million JPY | -35.48% |
| 2017 Q4 | -437.93 Million JPY | 80.73% |
| 2016 FY | - JPY | 12.09% |
| 2016 Q4 | -400.09 Million JPY | 45.9% |
| 2016 Q1 | -655.44 Million JPY | 58.37% |
| 2016 Q2 | -521.75 Million JPY | 20.4% |
| 2016 Q3 | -739.5 Million JPY | -41.73% |
| 2015 Q1 | -418.87 Million JPY | -147.06% |
| 2015 Q3 | -382.04 Million JPY | -49.76% |
| 2015 FY | - JPY | -137.44% |
| 2015 Q4 | -1.57 Billion JPY | -312.08% |
| 2015 Q2 | -255.11 Million JPY | 39.09% |
| 2014 Q3 | -227.56 Million JPY | 12.32% |
| 2014 FY | - JPY | 31.11% |
| 2014 Q4 | -169.53 Million JPY | 25.5% |
| 2014 Q2 | -259.54 Million JPY | 42.81% |
| 2014 Q1 | -453.85 Million JPY | -9.76% |
| 2013 Q2 | -459.79 Million JPY | -30.47% |
| 2013 Q3 | -375.66 Million JPY | 18.3% |
| 2013 Q4 | -413.51 Million JPY | -10.07% |
| 2013 FY | - JPY | 7.41% |
| 2013 Q1 | -352.41 Million JPY | 25.45% |
| 2012 Q3 | -360.99 Million JPY | 5.05% |
| 2012 Q4 | -472.71 Million JPY | -30.95% |
| 2012 FY | - JPY | 17.53% |
| 2012 Q1 | -515.43 Million JPY | -57.97% |
| 2012 Q2 | -380.19 Million JPY | 26.24% |
| 2011 Q1 | -390.68 Million JPY | 0.0% |
| 2011 Q2 | -304.89 Million JPY | 21.96% |
| 2011 Q3 | -1.06 Billion JPY | -249.2% |
| 2011 Q4 | -326.28 Million JPY | 69.35% |
| 2011 FY | - JPY | -248.79% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | - JPY | -193.69% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | - JPY | -247.54% |
| 2008 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 111.858% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 100.082% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 99.746% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 100.382% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | 225.05% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 101.967% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 105.82% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 100.692% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | 155.22% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 103.893% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 107.957% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 119.455% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 150.891% |
| Tsumura & Co. | 30.77 Billion JPY | 102.32% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 103.814% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 113.546% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 102.009% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 110.375% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 104.075% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 106.935% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 80.96% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 109.453% |
| MedRx Co., Ltd | -884.51 Million JPY | 19.278% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 112.897% |
| Solasia Pharma K.K. | -635 Million JPY | -12.441% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 69.923% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 107.792% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 101.936% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | -32.643% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 102.763% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 113.995% |